Screening for Multisystem Functional Vulnerability Across Complex Care Populations

Abstract

Multisystem functional vulnerability (MFV) represents a critical challenge in complex care populations, encompassing individuals with multiple chronic conditions, frailty, or advanced age. Early identification through systematic screening is essential for optimizing outcomes, allocating resources, and guiding multidisciplinary interventions. This review synthesizes recent evidence on epidemiology, mechanisms, risk factors, clinical presentation, and diagnostic approaches to MFV, with a focus on emerging tools and current guideline recommendations for screening in complex care settings.

Introduction

The increasing prevalence of patients with complex health needs, often characterized by multimorbidity, polypharmacy, and functional decline, necessitates robust strategies for early detection of multisystem functional vulnerability. MFV refers to the diminished reserve and resilience across multiple organ systems, predisposing individuals to adverse health outcomes, hospitalizations, and mortality. Systematic screening for MFV in complex care populations supports proactive care planning, risk stratification, and targeted interventions. This article provides an evidence-based overview of MFV screening, informed by recent research and evolving clinical guidelines.

Epidemiology / Disease Burden

Complex care populations, including older adults, individuals with chronic illnesses, and those with disabilities, represent a growing segment of healthcare utilization. Studies estimate that 20–30% of older adults exhibit some degree of MFV, with higher prevalence in institutionalized or post-acute care settings. MFV is associated with increased rates of hospitalization, rehospitalization, institutionalization, and mortality. The economic burden is significant, as individuals with MFV experience higher healthcare resource utilization, longer hospital stays, and frequent transitions of care. Recent cohort studies highlight that early identification and management of MFV can mitigate these adverse outcomes and improve quality of life.

Pathophysiology

MFV arises from complex, interrelated mechanisms involving physiological aging, chronic disease burden, and cumulative organ system insults. Loss of homeostatic reserve in cardiovascular, respiratory, renal, neurological, and musculoskeletal systems underlies the vulnerability. Chronic low-grade inflammation ("inflammaging"), neuroendocrine dysregulation, sarcopenia, and microvascular compromise contribute to reduced adaptive capacity. Repeated stressors, such as acute illness or iatrogenic insults, further erode multisystem resilience. The pathophysiological interplay between comorbidities accelerates the transition from compensated to decompensated states, increasing susceptibility to functional decline and adverse outcomes.

Risk Factors

Several risk factors predispose individuals to MFV, including advanced age, multiple chronic diseases (e.g., heart failure, COPD, CKD, diabetes), polypharmacy, frailty, cognitive impairment, malnutrition, and social determinants such as low socioeconomic status and limited access to care. Recent studies underscore the role of cumulative disease burden, medication-related adverse effects, and environmental stressors in amplifying functional vulnerability. Identifying high-risk subgroups is essential for the effective implementation of targeted screening protocols.

Clinical Features

MFV manifests as a spectrum of functional impairments, including reduced mobility, impaired activities of daily living (ADLs), cognitive decline, recurrent falls, fluctuating mental status, and increased susceptibility to infections or delirium. Clinicians should recognize subtle signs such as unexplained weight loss, fatigue, orthostatic hypotension, and diminished physiologic reserve during acute stress. Comprehensive clinical assessment must encompass physical, cognitive, psychosocial, and environmental domains to capture the multidimensional nature of MFV.

Diagnosis

Screening for MFV relies on multidimensional assessment tools that evaluate physical, cognitive, and psychosocial function. Validated instruments such as the Clinical Frailty Scale (CFS), Comprehensive Geriatric Assessment (CGA), Edmonton Frail Scale, and Multidimensional Prognostic Index (MPI) are widely used. These tools integrate objective measures (gait speed, grip strength, cognitive tests) with subjective assessments (ADLs, mood, nutrition). Biomarkers (e.g., inflammatory markers, natriuretic peptides) and digital health technologies offer emerging adjuncts for risk stratification. Effective screening requires regular reassessment, particularly after acute events or treatment changes.

Treatment & Management

Management of patients identified with MFV is inherently multidisciplinary, focusing on individualized care plans, medication optimization, nutritional support, physical rehabilitation, and psychosocial interventions. Early involvement of geriatricians, pharmacists, physiotherapists, and social workers enhances care coordination. Polypharmacy review and deprescribing, fall prevention strategies, and tailored physical activity programs are critical components. Advanced care planning and shared decision-making should be prioritized to align care with patient values and goals.

Recent Advances / Emerging Therapies

Technological innovations such as wearable sensors, telemedicine, and digital health platforms enable continuous monitoring of functional status and early detection of functional decline. Machine learning algorithms applied to electronic health records can improve risk prediction and guide personalized interventions. Novel biomarkers and omics-based profiling are under investigation for refining MFV phenotyping. Interventional studies on multimodal interventions, including combined exercise, nutrition, and cognitive training, show promise in mitigating MFV progression.

Guideline Recommendations

Recent guidelines from the American Geriatrics Society, European Geriatric Medicine Society, and other authoritative bodies advocate for routine MFV screening in high-risk populations, particularly those with multimorbidity, recent hospitalization, or unexplained functional decline. Recommended approaches include the use of validated frailty and functional assessment tools as part of routine clinical practice, with subsequent referral for comprehensive assessment and multidisciplinary management when indicated. Guidelines emphasize the importance of integrating MFV screening into care transitions and chronic disease management pathways.

Conclusion

Screening for multisystem functional vulnerability is a cornerstone of quality care for complex care populations. Early identification enables timely, targeted interventions that can prevent adverse outcomes, optimize resource allocation, and enhance patient-centered care. Implementation of evidence-based screening tools, multidisciplinary collaboration, and integration of new technologies will continue to advance the field and improve outcomes for vulnerable patients.